CION Ameerpet
Understanding Your Report · Reviewed by CION Oncologists · NABH Accredited
Type 1 Endometrial Cancer — The Common, Favourable Type
If your report says endometrioid carcinoma, you have the type that accounts for the large majority of endometrial cancers — and it is the favourable one. Type 1 tumours arise from prolonged oestrogen exposure, are usually low grade, are typically caught early because they bleed, and carry a considerably better outlook than the other types. That is a genuinely reassuring paragraph and it needs one qualification: Grade 3 endometrioid tumours behave differently from Grades 1 and 2, and are treated more seriously. So the type is good news; the grade completes the picture.
- The large majority of cases — endometrioid carcinoma is what most women with this diagnosis have
- Driven by oestrogen — which is why the risk factors are weight, cycles and hormone exposure
- Usually caught early — because it bleeds, and because it follows a precancer stage
- Grade still matters within it — Grade 3 endometrioid is a different proposition from Grade 1
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What “Endometrioid” Actually Means
The word is descriptive rather than technical: it means the tumour still resembles endometrium. Normal uterine lining is made of glands, and an endometrioid carcinoma continues to form glandular structures — abnormal ones, but recognisably derived from the tissue it arose in.
That resemblance is not cosmetic. It reflects a whole set of behaviours:
- It arises from oestrogen exposure. This is the tumour that the unopposed-oestrogen mechanism produces, which is why the risk factors are weight, anovulation and hormone therapy. See how excess oestrogen drives endometrial cancer.
- It is usually preceded by hyperplasia. There is a detectable, treatable precancer stage before it — which is why this disease has a genuine prevention story. See endometrial hyperplasia.
- It generally stays put longer. Compared with the non-endometrioid types, it is less prone to early spread within the abdomen, which is a large part of why it is usually diagnosed at stage I.
- It often keeps its hormone receptors. Which opens treatment options that hormone-independent tumours do not have.
You may also see this called endometrioid adenocarcinoma — adenocarcinoma simply means a cancer arising from glandular tissue. Same thing. See endometrioid adenocarcinoma explained.
Did You Know? Type 1 endometrial cancers are frequently rich in oestrogen and progesterone receptors, and that single property does more clinical work than most patients realise. It is why fertility-sparing treatment is possible at all in selected young women — the tumour responds to progestin, so hormones can substitute for surgery while a woman tries to conceive. It is why low-grade advanced or recurrent disease can sometimes be held in check for a long time with progestin therapy rather than chemotherapy, at a fraction of the toxicity. A tumour that still listens to hormonal signals gives you a lever that a hormone-independent tumour does not. Sources: World Health Organization classification of tumours of female reproductive organs; The Cancer Genome Atlas integrated genomic characterisation of endometrial carcinoma; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESGO–ESTRO–ESP guidelines.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Type 1 Compared With Type 2
The contrast is what makes the classification useful, even though it has been partly superseded.
| Type 1 (endometrioid) | Type 2 (non-endometrioid) | |
|---|---|---|
| How common | The large majority of endometrial cancers. | A minority — serous, clear cell and carcinosarcoma. See Type 2. |
| What drives it | Prolonged unopposed oestrogen. The risk factors are weight, anovulation, hormone therapy. | Not oestrogen-driven. Often arises on a thin atrophic lining in an older woman. |
| Precancer stage | Yes — endometrial hyperplasia, which is detectable and treatable. | Generally none of the same kind, which removes that window of opportunity. |
| Typical grade | Usually Grade 1 or 2, though Grade 3 endometrioid exists and behaves differently. | Regarded as high grade by definition, and not given a 1–3 grade. |
| Hormone receptors | Frequently positive, which opens hormone treatment options. | Frequently negative, so hormonal approaches are less useful. |
| Stage at diagnosis | Usually confined to the uterus. | More often spread beyond the uterus at presentation, including within the abdomen. |
| Treatment after surgery | Frequently none for low-grade early disease. See the adjuvant decision. | Usually recommended, often including chemotherapy, even at early stage. |
An important limitation of this whole table: the Type 1 / Type 2 split is a useful shorthand that has been largely superseded by molecular classification. Endometrial cancers are now sorted into four molecular groups which predict behaviour better than the two-way division — and some tumours that look Type 1 down the microscope turn out to carry a p53 abnormality and behave like Type 2, or vice versa. See MMR and MSI testing.
Endometrioid on Your Report and Wondering What Follows?
The type is favourable. Grade, depth of invasion and molecular group decide the rest — and they are on the same page.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
The Common Type Is Also the Favourable One
Which is why most women with endometrial cancer are treated with surgery and need nothing afterwards.
Where the Reassurance Stops
A page about the favourable type has an obligation to say where the favourability runs out, because a woman with Grade 3 endometrioid disease should not read this and conclude her situation is straightforward.
- Grade 3 endometrioid behaves differently. More than half the tumour growing as solid sheets rather than glands, associated with deeper invasion and a higher chance of nodal spread. It is managed more intensively than Grades 1 and 2 and is often grouped with the high-grade cancers. See Grade 3 endometrial cancer.
- Substantial lymphovascular invasion changes the picture. Tumour cells inside the small vessels of the uterine wall indicate a route to travel by, and it raises the risk category independently of type and grade.
- A p53 abnormality overrides the type. An endometrioid tumour carrying a p53 abnormality is treated as high risk regardless of how favourable its appearance suggests it should be. This is exactly why molecular testing has displaced the two-type model.
- Stage still matters. A Type 1 tumour that has reached the lymph nodes is stage III and is treated as such. Favourable histology does not undo anatomical spread. See stage 3.
The honest summary: Type 1 is the best of the four things on your report to have, and it is one of four. Ask for all of them together.
Want to Know Whether You Need Treatment After Surgery?
For low-grade Type 1 disease the answer is often no — and that is worth establishing rather than assuming either way. The opinion is free.
What Treatment Usually Looks Like
For low-grade, early-stage Type 1 disease, which is the commonest situation in this diagnosis.
Almost always
Surgery
Removal of the uterus and cervix, usually with tubes and ovaries, generally by keyhole or robotic route. Frequently the whole of the treatment. See what to expect.
Often
Node Assessment
Increasingly by sentinel node mapping, which gives staging information with far less risk of leg lymphoedema than extensive dissection. See sentinel node biopsy.
Frequently nothing
No Further Treatment
Low grade, shallow invasion, no substantial vessel involvement — international guidance supports surgery alone for this group, and it is a large group.
Sometimes
Vault Brachytherapy
A short internal radiation course for intermediate-risk disease, targeting the site where local recurrence usually appears. See the experience.
Selected women
Fertility-Sparing Treatment
For a young woman with a Grade 1 tumour confined to the lining, progestin can substitute for surgery temporarily. See fertility and endometrial cancer.
Advanced disease
Hormone Therapy
Where receptors are positive and disease is low grade, progestin can control advanced or recurrent disease with far less toxicity than chemotherapy. See hormone therapy.
Why the Favourable Type Still Deserves a Careful Team
Early, low-grade disease is where over-treatment does the most avoidable harm — and where getting it right is most achievable.
Tumour board for every diagnosis
Slides reviewed, not just the summary line
MMR / MSI testing as standard
Sentinel node mapping where it fits
Fertility taken seriously
Decisions for healing, not billing
Take The Next Step
This Is the Type Most Often Cured by the Operation Alone
The useful question now is what, if anything, needs to follow it.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Type 1 Endometrial Cancer — Frequently Asked Questions
What does Type 1 endometrial cancer mean?
It means the tumour is an endometrioid carcinoma arising from prolonged oestrogen stimulation of the uterine lining. "Endometrioid" describes what the pathologist sees: the tumour still forms glandular structures resembling normal endometrium. This is the commonest form of endometrial cancer by a wide margin, it is typically preceded by endometrial hyperplasia, it is usually low grade, it frequently retains oestrogen and progesterone receptors, and it is generally confined to the uterus when diagnosed because it causes abnormal bleeding early. It carries a more favourable outlook than the non-endometrioid types, which are collectively called Type 2.
Is Type 1 endometrial cancer less serious?
On average yes, and that average conceals real variation. Type 1 tumours are usually low grade, usually early stage, and frequently treated by surgery alone with nothing needed afterwards — which is a genuinely favourable position. But Grade 3 endometrioid carcinoma behaves considerably less favourably than Grades 1 and 2 and is managed more intensively, often grouped with the high-grade cancers. Substantial lymphovascular space invasion raises risk independently. And an endometrioid tumour that carries a p53 abnormality on molecular testing is treated as high risk regardless of its favourable appearance. The type is the best single thing to have on your report; it is not the only thing on it.
Why does it matter whether my tumour has hormone receptors?
Because it gives you a treatment lever that hormone-independent tumours do not have. Type 1 endometrioid cancers are frequently rich in oestrogen and progesterone receptors, meaning they still respond to hormonal signals. This is what makes fertility-sparing treatment possible in selected young women — high-dose progestin can substitute for surgery temporarily while a woman tries to conceive. It also means that low-grade advanced or recurrent disease can sometimes be controlled for a considerable period with progestin therapy rather than chemotherapy, at substantially lower toxicity. Receptor status is assessed on the tumour tissue and is worth asking about.
Is the Type 1 and Type 2 classification still used?
It remains a useful shorthand and it has been largely superseded for clinical decision-making. Endometrial cancers are now sorted into four molecular groups — POLE-mutated, mismatch repair deficient, p53-abnormal, and no specific molecular profile — which predict behaviour better than the two-way histological split and are incorporated into the current FIGO staging system. The reason the older model was displaced is that it misclassified a meaningful minority: some tumours that look endometrioid under the microscope carry a p53 abnormality and behave aggressively, while some high-grade tumours turn out to be POLE-mutated and behave very well. Both classifications appear in reports.
Will I need treatment after surgery for Type 1 cancer?
For a substantial group, no. A Grade 1 or 2 endometrioid tumour invading less than half the muscle wall, with no substantial lymphovascular invasion, is classed as low risk, and international guidance supports surgery alone with no radiation — treating everyone in that group would expose many women to side effects to benefit very few. Intermediate-risk disease is usually offered a short course of vaginal vault brachytherapy. Higher-risk features — deep invasion combined with high grade, substantial vessel involvement, node involvement, or a p53-abnormal molecular group — bring pelvic radiation or drug treatment into the discussion. The decision is made on the final surgical pathology.
Medical disclaimer: This page explains Type 1 endometrioid endometrial cancer in general terms and is reviewed by a CION oncologist, following the World Health Organization classification and current NCCN and ESGO–ESTRO–ESP guidance. It describes tumour behaviour at a population level and does not predict an outcome for any individual. It is not an interpretation of your own pathology report; treatment decisions should be made with the oncology team holding your full pathology and molecular testing results.